View in EDS

352TiP Randomized phase III study of daratumumab (D) versus bortezomib plus D as a maintenance therapy after D-MPB for elderly or non-elderly patients refusing transplant with untreated multiple myeloma (JCOG1911, B-DASH study).

Saved in:
Bibliographic Details
Title: 352TiP Randomized phase III study of daratumumab (D) versus bortezomib plus D as a maintenance therapy after D-MPB for elderly or non-elderly patients refusing transplant with untreated multiple myeloma (JCOG1911, B-DASH study).
Authors: Suzuki, T.1 (AUTHOR), Maruyama, D.2 (AUTHOR), Machida, R.3 (AUTHOR), Ito, Y.4 (AUTHOR), Kataoka, K.5 (AUTHOR), Nagai, H.6 (AUTHOR)
Source: Annals of Oncology. 2023 Supplement 4, Vol. 34, pS1606-S1606. 1p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1016/j.annonc.2023.10.734